



PFW

From:
Zhifang Zhu
6540 Bellows Lane, 1102b
Houston, TX 77030
Tel: 713-933-4383

BEST AVAILABLE COPY

To: USA Patent and Trademark Office
Commissioner for patents
PO Box 1450
Alexandria, Virginia 22313-1450

03/20/06

Dear USA patent office:

Due to the factor that Gene Cloning Inc is not able to support patent lawyers spending. The applied patent (application #10/613,390) will be responded by Zhifang Zhu, the principle inventor. The current contact information is:

Zhifang Zhu
6540 Bellows lane, 1102b
Houston, TX 77030
Tel: 713-933-4383

Thanks!

Zhifang Zhu



Response to: Art unit 1633 (application# 10/613,390)

Date: 03/20/06

By: Zhifang Zhu

Election/Restrictions.

2.

A. DNA-binding protein or RNA primers (claim 1).

According to current knowledge, DNA-binding proteins binding DNA and RNA as primers in DNA duplication process are universal process in any species. However, we have done the model with mice cancer cells and human cancer cells. To fit 35 U.S.C. 121, we elect Human.

B. Leukemia, lung cancer or melanoma (claim 6).

We have tested mouse leukemia and melanoma, and human lung cancer models.

C. RNA polymerase, transcription factors, activators, repressors or regulatory proteins (claim 11).

Research shows that RNA polymerase, transcription factors, activators, repressors or regulatory proteins are universal factors in biological system. However we have detected in mouse and human cancer cell models. To fit 35 U.S.C. 121, we elect human.

D. RNA polymerase-binding elements, transcription factor-binding elements, activator-binding elements, repressor-binding elements, GC-rich regions or single stranded nucleotide protein binding-elements (claim 13).

GC-rich region composed of gene promoter involving gene transcription. It is the elements for RNA-polymerase-binding, transcription factor-binding, activator-binding, repressor-binding. The process is universal in biological system. However, we have tested in mouse and human cancer cells. To fit 35 U.S.C. 121, we elect human.

3.

A. From about 2-40 (claim 14) or from 7-25 (claim 15) bases long.

Practically, we have used 7 bases and 25 bases long DNA oligos in our experiment at the time we applied for patent. Further experiments that with random single strand DNA from 2 bases to over 100 bases shows significant results in Human lung cancer cells and mouse leukemia cancer cells. To fit 35 U.S.C. 121, we elect human.

B. From about 5-40 (claim 3) or from about 7 to 25 (claim 4) bases long.

The claim 3 and claim 4 are included in claim 14. They should be elected with human too.